Journal: International Journal of Immunopathology and Pharmacology
Article Title: A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition
doi: 10.1177/03946320221105134
Figure Lengend Snippet: The bFGFmAb and its characteristics. (a) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified bFGFmAb (H, heavy chain; L, light chain). (b) Concentration of the purified bFGFmAb stock solution determined by bicinchoninic acid (BCA) standard assays. (c) Titer of the purified bFGFmAb stock solution tested by indirect ELISA. (d) The bFGFmAb inhibits the proliferation of A549 and A549/DDP cells. (e) Treatment with bFGF increases the proliferation in A549 and A549/DDP cells. bFGF, basic fibroblast growth factor; DDP, cisplatin; ELISA, enzyme-linked immunosorbent assay; mAb, monoclonal antibody; OD, optical density.
Article Snippet: After blocking with 5% blotto (skimmed milk) in Tris-buffered saline and Tween 20 for 1 h, the primary antibodies rabbit monoclonal anti-bFGF (CST, USA; 1:1000 dilution), mouse monoclonal anti-E-cadherin (CST, 1:1000 dilution), rabbit polyclonal anti-N-cadherin (Abcam, UK; 1:1000 dilution), rabbit polyclonal anti-LRP (Santa Cruz, USA, 1:200 dilution), and mouse monoclonal anti-β-actin (CST, USA, 1:1000 dilution) were added and incubated at 4°C overnight.
Techniques: Polyacrylamide Gel Electrophoresis, Purification, Concentration Assay, Indirect ELISA, Enzyme-linked Immunosorbent Assay